These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2266710)

  • 1. [D-penicillamine-induced IgA deficiency in the therapy of Wilson's disease].
    Ibel H; Feist D; Endres W; Belohradsky BH
    Klin Padiatr; 1990; 202(6):427-9. PubMed ID: 2266710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early onset of nephrotic syndrome after treatment with D-penicillamine in a patient with Wilson's disease.
    Siafakas CG; Jonas MM; Alexander S; Herrin J; Furuta GT
    Am J Gastroenterol; 1998 Dec; 93(12):2544-6. PubMed ID: 9860423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease.
    Hanukoglu A; Curiel B; Berkowitz D; Levine A; Sack J; Lorberboym M
    J Pediatr; 2008 Dec; 153(6):864-6. PubMed ID: 19014823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [D-penicillamin-induced IgA-deficiency (author's transl)].
    Götze H
    Klin Padiatr; 1979 Jul; 191(4):433-5. PubMed ID: 314018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The detection of antibodies against D-penicillamine. 3. Detection of antibodies against D-penicillamine in the serum of patients with Wilson's disease treated with D-penicillamine--preliminary results].
    Trautmann B; Storch W
    Pharmazie; 1986 Feb; 41(2):126-7. PubMed ID: 3523546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oral zinc in Wilson disease--an alternative to D-penicillamine].
    Ramadori G; Keidl E; Hütteroth T; Dormeyer HH; Manns M; Meyer zum Büschenfelde KH
    Z Gastroenterol; 1985 Jan; 23(1):25-9. PubMed ID: 4060799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease.
    Ping CC; Hassan Y; Aziz NA; Ghazali R; Awaisu A
    J Clin Pharm Ther; 2007 Feb; 32(1):101-7. PubMed ID: 17286794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [On hepatolenticular degeneration (Wilson's disease). II. Treatment of 2 cases of Wilson's disease for 8 months with D-penicillamine].
    Germinario L; Campanella G; D'Addabbo A
    Acta Neurol (Napoli); 1971; 26(4):423-35. PubMed ID: 5132824
    [No Abstract]   [Full Text] [Related]  

  • 9. D-penicillamine-induced IgA deficiency in Wilson's disease.
    Proesmans W; Jaeken J; Eeckels R
    Lancet; 1976 Oct; 2(7989):804-5. PubMed ID: 61477
    [No Abstract]   [Full Text] [Related]  

  • 10. [Nephrotic syndrome after treatment with penicillamine in Wilson's disease].
    Hampel R; Meng W; Kallwellis G
    Z Gesamte Inn Med; 1976 Jul; 31(13):507-11. PubMed ID: 960872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Experiences with penicillamine in Wilson's disease].
    Lössner J; Bachmann H; Eichner B
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():48-53. PubMed ID: 829635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term treatment of Wilson's disease with D-penicillamine. Report on 20 cases].
    Lange J
    Dtsch Med Wochenschr; 1967 Sep; 92(37):1657-62. PubMed ID: 6054323
    [No Abstract]   [Full Text] [Related]  

  • 13. [Systemic lupus erythematosus induced by d-penicillamine in Wilson's disease: apropos of a case].
    López-Guerra N; Alvarez Lario B; García-Moncó C; Peña Sagredo JL
    Med Clin (Barc); 1987 Apr; 88(13):552-4. PubMed ID: 3586738
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immunologic studies with the lymphocyte transformation test on the side effects of D-penicillamine therapy in Wilson's disease].
    Storch W; Berger H
    Z Gesamte Inn Med; 1980 Jul; 35(13):567-70. PubMed ID: 7445606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dermatological complications during treatment of Wilsons disease with D-penicillamine].
    Rimbaud P; Mirouze J; Mary P; Meynadier J
    Med Chir Dig; 1973; 2(1):3-8. PubMed ID: 4269689
    [No Abstract]   [Full Text] [Related]  

  • 16. Dermal alterations in patients with Wilson's disease treated with D-penicillamine.
    Pasquali Ronchetti I; Quaglino D; Baccarani Contri M; Hayek J; Galassi G
    J Submicrosc Cytol Pathol; 1989 Jan; 21(1):131-9. PubMed ID: 2702608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Long-term D-penicillamine therapy of Wilson's disease in childhood. Changes in blood coagulation and effects on the haematopoetic system].
    Hayek HW; Schnack H; Widhalm S
    Wien Klin Wochenschr; 1973 Feb; 85(8):122-5. PubMed ID: 4632215
    [No Abstract]   [Full Text] [Related]  

  • 18. Elastosis perforans serpiginosa secondary to D-penicillamine treatment in a Wilson's disease patient.
    Deguti MM; Mucenic M; Cancado EL; Tietge UJ
    Am J Gastroenterol; 2002 Aug; 97(8):2153-4. PubMed ID: 12190204
    [No Abstract]   [Full Text] [Related]  

  • 19. [Serious side effects with D-penicillamine therapy for Wilson's disease].
    Storch W; Lössner J; Ruchholtz U
    Psychiatr Neurol Med Psychol (Leipz); 1979 Sep; 31(9):531-8. PubMed ID: 161403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Wilson's disease in children. Five case reports].
    Landrieu P; Choulot JJ
    Arch Fr Pediatr; 1976; 33(7):665-75. PubMed ID: 999439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.